首页> 外文期刊>Frontiers in Chemistry >Homology modeling informs ligand discovery for the glutamine transporter ASCT2
【24h】

Homology modeling informs ligand discovery for the glutamine transporter ASCT2

机译:同源性建模提示谷氨酰胺转运蛋白ASCT2的配体发现

获取原文
           

摘要

The Alanine-Serine-Cysteine transporter (SLC1A5, ASCT2), is a neutral amino acid exchanger involved in the intracellular homeostasis of amino acids in peripheral tissues. Given its role in supplying glutamine to rapidly proliferating cancer cells in several tumor types such as triple-negative breast cancer and melanoma, ASCT2 has been identified as a key drug target. Here we use a range of computational methods, including homology modeling and ligand docking, in combination with cell-based assays, to develop hypotheses for structure-function relationships in ASCT2. We perform a phylogenetic analysis of the SLC1 family and its prokaryotic homologs to develop a useful multiple sequence alignment for this protein family. We then generate homology models of ASCT2 in two different conformations, based on the human EAAT1 structures. Using ligand enrichment calculations, the ASCT2 models are then compared to crystal structures of various homologs for their utility in discovering ASCT2 inhibitors. We use virtual screening, cellular uptake and electrophysiology experiments to identify a non-amino acid ASCT2 inhibitor that is predicted to interact with the ASCT2 substrate binding site. Our results provide insights into the structural basis of substrate specificity in the SLC1 family, as well as a framework for the design of future selective and potent ASCT2 inhibitors as cancer therapeutics.
机译:丙氨酸-丝氨酸-半胱氨酸转运蛋白(SLC1A5,ASCT2)是一种中性氨基酸交换剂,参与外周组织氨基酸的细胞内稳态。鉴于ASCT2可以为多种肿瘤类型(例如三阴性乳腺癌和黑色素瘤)的快速增殖的癌细胞提供谷氨酰胺,因此ASCT2被确定为关键药物靶标。在这里,我们使用一系列计算方法,包括同源性建模和配体对接,再结合基于细胞的分析方法,来为ASCT2中的结构-功能关系建立假设。我们对SLC1家族及其原核同源物进行系统发育分析,以开发该蛋白家族的有用的多序列比对。然后,基于人类EAAT1结构,我们以两种不同的构型生成ASCT2的同源性模型。使用配体富集计算,然后将ASCT2模型与各种同源物的晶体结构进行比较,以发现ASCT2抑制剂。我们使用虚拟筛选,细胞吸收和电生理实验来确定一种非氨基酸ASCT2抑制剂,该抑制剂预计与ASCT2底物结合位点相互作用。我们的结果提供了对SLC1家族中底物特异性的结构基础的见识,以及为将来设计选择性和有效ASCT2抑制剂作为癌症治疗药物设计的框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号